Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
GHK-Cu
Copper Peptide, Glycyl-L-histidyl-L-lysine:copper(II)
A cosmetic peptide that mimics the N-terminal end of SNAP-25, a protein involved in neuromuscular signaling. By competing with SNAP-25 for a position in the SNARE complex, it reduces the intensity of muscle contractions that cause expression lines. Often called 'topical Botox' in the skincare industry, though its effects are much milder than injectable neurotoxins.
A naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Levels decline significantly with age. Widely used in both injectable and topical forms for anti-aging.
Competes with natural SNAP-25 for binding in the SNARE complex, which is required for neurotransmitter release at the neuromuscular junction. By partially inhibiting SNARE complex formation, it reduces acetylcholine release and softens muscle contractions that create wrinkles. Works topically — no injection required.
Activates wound healing genes, promotes collagen and elastin synthesis, stimulates blood vessel growth, and has anti-inflammatory and antioxidant properties. The copper ion is essential for many enzymatic processes in tissue remodeling.
- Anti-wrinkle skincare
- Expression line reduction
- Forehead and crow's feet treatment
- Anti-aging cosmetic formulations
- Skin rejuvenation and anti-aging
- Wound healing
- Hair growth stimulation
- Collagen production
- Reducing inflammation
- Mild skin irritation in sensitive individuals
- Effects are subtle compared to injectable treatments
- Efficacy varies significantly between formulations
- Not a replacement for Botox or dermal fillers
- Generally well-tolerated topically
- Injectable form has less safety data
- Potential copper toxicity at high doses
- Skin irritation possible with topical use
Not FDA-regulated as a drug. Classified as a cosmetic ingredient. Widely used in over-the-counter skincare products globally. No prescription required. Regulated under cosmetic ingredient safety standards rather than pharmaceutical standards.
GHK-Cu has a notably complex status after the April 15, 2026 FDA announcement. Injectable GHK-Cu is being removed from Category 2 (significant safety risks), while non-injectable GHK-Cu is simultaneously being removed from Category 1 (active evaluation). Both forms are scheduled for a unified PCAC review before February 2027. Topical cosmetic use is unaffected. Injectable use is now in regulatory gray zone — compounding pharmacies should not assume authorization until PCAC acts.
PCAC: By February 2027
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.